ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • Search
  • My Favorites
    • View and print all favorites
    • Clear all favorites

Abstract Number: 2324

Metabolic Syndrome and Early Arthritis: Frequency, Association with Antibodies Profile and Disease Activity

Francisco Guiñazú1, Carla Gobbi 2, Paula Alba 1, Carla Maldini 3, Carla Alonso 1, Alejandro Albiero 1, Eduardo Albiero 1, Viviana Neme 4, Marcela Demarchi 4 and Marcelo Yorio 3, 1UNIDAD DE REUMATOLOGÍA, CÁTEDRA DE SEMIOLOGÍA, HOSPITAL CÓRDOBA, FACULTAD DE CIENCIAS MÉDICAS, UNIVERSIDAD NACIONAL DE CÓRDOBA, ARGENTINA, Cordoba, Cordoba, Argentina, 2CÁTEDRA DE CLÍNICA MÉDICA I, HOSPITAL CÓRDOBA, FACULTAD DE CIENCIAS MÉDICAS, UNIVERSIDAD NACIONAL DE CÓRDOBA, ARGENTINA, Cordoba, Cordoba, Argentina, 3CÁTEDRA DE SEMIOLOGÍA, HOSPITAL CÓRDOBA, FACULTAD DE CIENCIAS MÉDICAS, UNIVERSIDAD NACIONAL DE CÓRDOBA, ARGENTINA, Cordoba, Cordoba, Argentina, 4SERVICIO DE BIOQUÍMICA. HOSPITAL CÓRDOBA, ARGENTINA, Cordoba, Cordoba, Argentina

Meeting: ACR/ARP Annual Meeting 2019

Keywords: Arthritis, Disease Activity and atherosclerosis, Early Rheumatoid Arthritis, metabolic syndrome

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: RA – Diagnosis, Manifestations, & Outcomes Poster III: Comorbidities

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: The Metabolic Syndrome (MetS) is an independent factor of cardiovascular morbidity and mortality and most studies show that its prevalence is higher in established Rheumatoid Arthritis (RA) than in the general population, which would be associated with systemic inflammatory activity. Few studies have evaluated this association in patients with Early Arthritis (EA) with different results. Objective: To study the frequency of MetS in patients with EA and its association with disease activity and antibodies profile.

Methods: We studied all the patients with diagnosis of EA who consecutively attended to Rheumatology Unit at Cordoba Hospital from August 2016 to February of 2018. EA was diagnosed by the presence of inflammation in 3 or more joints of less than 12 months duration.  A non-RA population was a control group, matched by age and gender.  Clinical and laboratory data were collected. The activity of the disease was evaluated by DAS28-ESR. The presence of MetS was evaluated according to 3 different international classification: World Health Organization 1998-1999 (WHO), Adult Treatment Panel III 2004 (ATPIII) e International Diabetes Federation 2005 (IDF). EA cases were analysed in to two groups according to MetS or not diagnosis (MetS+/MetS-). A chi-squared test and T-test or Mann–Whitney U test were applied for comparison of categorical and continuous variables as appropriate. P < 0.05 was considered statistically significant.

Results: Sixty-two EA patients were included. Demographic and clinical data are shown in table 1. Diagnosis criteria of MetS was more frequent in EA patients than in the control group according to the 3 definitions used (Table 2). In addition, EA patients with and without presence of MetS did not show statistically significant differences in ESR neither in CRP level. There was also no significant difference in level of RF and ACCP antibodies. On the other hand, there was no difference in DAS 28-ESR between EA patients with and without MetS. These results are shown in Table 3.

Conclusion: MetS seems to be more frequent in EA and its presence is not associated with disease activity and the presence of RF or ACCP antibodies. MetS is a known risk factor for cardiovascular disease, morbidity and mortality in systemic autoimmune diseases. A tight control of this condition in the early stages of disease should be recommended.

Note: all variables are expressed as mean and standard deviation -±SD- and compared using the T-test or Mann–Whitney U -*- except for females that are expressed in frequency and percentage -n -%– and compared using the chi-squared test.

Note: all variables are expressed in frequency and percentage -n -%– and compared using chi-squared test. ATP III: Adult Treatment Panel III. WHO: World Health Organization. IDF: International Diabetes Federation.

Note: continuous variables are expressed as mean and standard deviation and compared using the T-test or Mann–Whitney U -*-. Categorical are expressed in frequency and percentage and compared using chi-squared test. MetS: Metabolic syndrome. RF: Rheumatoid Factor. ACPA: Anti-citrullinated cyclic peptide antibodies. ESR: Erythrocyte sedimentation rate. CRP: C Reactive Protein. DAS28-ESR: Disease Activity Score of 28 joints with ESR.


Disclosure: F. Guiñazú, None; C. Gobbi, None; P. Alba, None; C. Maldini, None; C. Alonso, None; A. Albiero, None; E. Albiero, None; V. Neme, None; M. Demarchi, None; M. Yorio, None.

To cite this abstract in AMA style:

Guiñazú F, Gobbi C, Alba P, Maldini C, Alonso C, Albiero A, Albiero E, Neme V, Demarchi M, Yorio M. Metabolic Syndrome and Early Arthritis: Frequency, Association with Antibodies Profile and Disease Activity [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/metabolic-syndrome-and-early-arthritis-frequency-association-with-antibodies-profile-and-disease-activity/. Accessed .
  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to ACR/ARP Annual Meeting 2019

ACR Meeting Abstracts - https://acrabstracts.org/abstract/metabolic-syndrome-and-early-arthritis-frequency-association-with-antibodies-profile-and-disease-activity/

Advanced Search

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology